• Carmen Rubio, Fernando Gatica, Eric Uribe, Ernesto Ochoa, Victoria Campos, and Moisés Rubio-Osornio.
• Department of Neurophisiology, Instituto Nacional de Neurología y Neurocirugía, Mexico City, Mexico.
• Rev Invest Clin. 2023 Jan 1; 75 (1): 1121-12.

AbstractEpilepsy is a multifactorial pathology that has allowed the development of various drugs aiming to combat it. This effort was formally initiated in the 1940s when phenytoin began to be used. It eventually turned out to be a drug with great anticonvulsant efficacy. At present, several potentially good new generation anti-seizure medications (ASMs) have been developed. Most of them present more tolerability and less toxic effects. However, they continue to have adverse effects at different levels. In addition, some seizures are difficult to treat with ASMs, representing 30% of the total cases of people who suffer from epilepsy. This review aims to explore the genetic and molecular mechanisms of ASMs neurotoxicity, proposing the study of damage caused by epileptic seizures, in addition to the deterioration generated by anti-seizure drug administration within the central nervous system. It is beyond question that there is a need to develop drugs that lower the lower the risk of secondary and toxic effects of ASMs. Simultaneously, we must find strategies that produce fewer harmful interactions and more health benefits when taking anti-seizure drugs.Copyright: © 2023 Permanyer.

13 keywords...

hide…